Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

The cachexia hematologic severity score (CHeSS): Use of a laboratory-based tool to predict survival and mutation-associated wasting in Acute Myeloid Leukemia and myelodysplastic syndrome

View Full Paper
Ask AI
Bookmark
Share

Authors

ARAnisha RajavelSRSushmitha Nanja ReddyDPDakshin Padmanabhan

Discussion

Loading...

Member takes

Overview

This analysis shows that cachexia impacts survival in Acute Myeloid Leukemia and myelodysplastic syndrome, suggesting interventions may improve outcomes for at-risk patients.

Key Points

  • Cachexia significantly impacts survival, as patients with cachexia had lower survival rates than those without it.
  • Patients with progressive cachexia in AML showed a median overall survival of 13 months, while non-cachectic patients reached 102 months.
  • Retrospective analysis assessed cachexia using laboratory markers and weight loss grading in 203 patients with AML and MDS.
  • Identifying cachexia using a laboratory scoring tool may enable earlier interventions and supportive care for patients at risk.

Cite This Study

Rajavel et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0a9https://doi.org/10.1182/blood-2025-1735
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A health-system-scale, episode-resolved multimodal atlas of cancer cachexia2025
  2. 2Cancer Cachexia: A Meta-Analysis of Prevalence, Outcomes, and Interventions2025
  3. 3Cachexia index as a biomarker for cancer cachexia and quality of life in patients with gastric cancer2025
  4. 4Early Markers of Cardiac and Skeletal Muscle Metabolic Derangement in the Apc(min/+) Male Mouse.2025
  5. 5Skeletal Muscle Alterations and Functional Repercussions in Patients with Colorectal Cancer-associated Cachexia2025